- The company continues to expect full-year 2025 adjusted earnings to be in the range of $3.00 per share to $3.15 per share
- The revised forecast for FY25 revenue is $62 billion, compared to $61-64 billion estimated earlier
- For fiscal 2026, the management forecasts revenues in the range of $59.5 billion to $62.5 billion
- The guidance for revenues from COVID-19 products for FY26 is $5 billion
- FY26 operational revenue growth is expected to be 4% year-over-year, at the midpoint, excluding both COVID-19 and LOE products
- Full-year 2026 adjusted earnings are expected to be in the range of $2.80 per share to $3.00 per share
- The effective tax rate on adjusted income is expected to be approximately 15%
- The firm sees 2026 adjusted SI&A expenses in the range of $12.5 to $13.5 billion, reflecting its cost realignment program
Market News
Pfizer affirms FY25 earnings guidance, provides full-year 2026 outlook
Pfizer Inc. (NYSE: PFE) has reaffirmed its earnings outlook for fiscal 2025 and revised revenue guidance. The pharma giant also initiated guidance for fiscal 2026. The company continues to expect full-year 2025 adjusted earnings to be in the range of $3.00 per share to $3.15 per share The revised forecast for FY25 revenue is $62 […]
“Pfizer Inc. (NYSE: PFE) has reaffirmed its earnings outlook for fiscal 2025 and revised revenue guidance. The pharma giant also initiated guidance for fiscal 2026. The company continues to expect full-year 2025 adjusted earnings to be in the range of $3.00 per share to $3.15 per share The revised forecast for FY25 revenue is $62 […]
· December 17, 2025
Pfizer Inc. (NYSE: PFE) has reaffirmed its earnings outlook for fiscal 2025 and revised revenue guidance. The pharma giant also initiated guidance for fiscal 2026.
ADVERTISEMENT